Semaglutide

Semaglutide, sold under the brand names Ozempic, Wegovy and Rybelsus, is an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management, developed by Novo Nordisk in 2012.Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of the human incretin glucagon-like peptide-1 (GLP-1), thereby increasing insulin secretion and increasing blood sugar disposal and improving glycemic control.

Read more in the app

New evidence shows tirzepatide and semaglutide strongly protect the heart

Obesity drugs improve heart health: Study shows additional benefits of semaglutide and tirzepatide - EurekAlert!

The Lancet: Study confirms cardiovascular benefits of semaglutide beyond weight loss - EurekAlert!

Liraglutide vs semaglutide vs dulaglutide in veterans with type 2 diabetes - EurekAlert!

Nearly 20% Weight Loss Achieved With Higher Dose of Semaglutide, Study Finds

Semaglutide may silence the food noise in your head

Taking semaglutide turns down food noise, research suggests - EurekAlert!

The Lancet Diabetes & Endocrinology: Higher doses of semaglutide can safely enhance weight loss and improve health for adults living with obesity, two new clinical trials confirm - EurekAlert!

Semaglutide reduces cocaine use in rats - EurekAlert!

Semaglutide and tirzepatide in patients with heart failure with preserved ejection fraction - EurekAlert!

Ocular adverse events with semaglutide - EurekAlert!

Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes - EurekAlert!

Changes in cardiovascular risk factors and health care expenditures among patients prescribed semaglutide - EurekAlert!

Semaglutide Demonstrates Impressive Heart Benefits – Even Before You Lose Weight

Tirzepatide vs. Semaglutide: New Research Reveals Surprising Metabolic Differences

Reversing Liver Disease? Scientists Discover New Health Benefit of Semaglutide

Study reveals distinct mechanisms of action of tirzepatide and semaglutide - EurekAlert!

Semaglutide may provide early protection against heart disease in high-risk patients—even before clinically meaningful weight loss and prior to the full target dose - EurekAlert!

First head-to-head study in people living with obesity shows tirzepatide results in around 50% more weight loss than semaglutide - EurekAlert!

Patients of an online obesity clinic achieved the same weight loss as those in clinical trials of semaglutide – but with much lower doses of the drug - EurekAlert!